WallStSmart

Baxter International Inc (BAX)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 480% more annual revenue ($66.57B vs $11.47B). MRK leads profitability with a 4.8% profit margin vs -9.3%. MRK appears more attractively valued with a PEG of 2.76. BAX earns a higher WallStSmart Score of 54/100 (C-).

BAX

Buy

54

out of 100

Grade: C-

Growth: 6.7Profit: 3.5Value: 5.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.98

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BAXUndervalued (+51.0%)

Margin of Safety

+51.0%

Fair Value

$45.43

Current Price

$23.37

$22.06 discount

UndervaluedFair: $45.43Overvalued
MRKSignificantly Overvalued (-78.2%)

Margin of Safety

-78.2%

Fair Value

$83.04

Current Price

$148.81

$65.77 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BAX2 strengths · Avg: 8.0/10
Price/BookValuation
1.9x8/10

Reasonable price relative to book value

EPS GrowthGrowth
36.8%8/10

Earnings expanding 36.8% YoY

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$365.34B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

BAX4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.984/10

Grey zone — moderate risk

Debt/EquityHealth
1.563/10

Elevated debt levels

PEG RatioValuation
36.682/10

Expensive relative to growth rate

Return on EquityProfitability
-17.1%2/10

ROE of -17.1% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : BAX

The strongest argument for BAX centers on Price/Book, EPS Growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : BAX

The primary concerns for BAX are Altman Z-Score, Debt/Equity, PEG Ratio. Debt-to-equity of 1.56 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

BAX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

BAX carries more volatility with a beta of 0.59 — expect wider price swings.

BAX is growing revenue faster at 5.3% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

BAX scores higher overall (54/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baxter International Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?